keyword
MENU ▼
Read by QxMD icon Read
search

CIBMTR

keyword
https://www.readbyqxmd.com/read/28214979/improved-prognostic-stratification-power-of-cibmtr-risk-score-with-the-addition-of-absolute-lymphocyte-and-eosinophil-counts-at-the-onset-of-chronic-gvhd
#1
Joon Ho Moon, Nada Hamad, Sang Kyun Sohn, Jieun Uhm, Naheed Alam, Vikas Gupta, Jeffrey H Lipton, Hans A Messner, Matthew Seftel, John Kuruvilla, Dennis Dong Hwan Kim
The CIBMTR chronic graft-versus-host disease (cGVHD) risk score can be refined and improved for better prognostic stratification. Three hundred and seven consecutive patients diagnosed with cGVHD by the NIH consensus criteria were retrospectively reviewed and had the CIBMTR risk score applied and analyzed. The CIBMTR risk score was successfully validated in our cohort (n = 307). The 3-year overall survival (OS) rates in each risk group (RG) were 82.5 ± 11.3% (RG1), 79.4 ± 3.0% (RG2), 71.8 ± 6.3% (RG3), and 27...
February 18, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28161608/allogeneic-hematopoietic-cell-transplantation-for-aggressive-nk-cell-leukemia-a-center-for-international-blood-and-marrow-transplant-research-analysis
#2
Mehdi Hamadani, Abraham S Kanate, Alyssa DiGilio, Kwang Woo Ahn, Sonali M Smith, Jong Wook Lee, Ernesto Ayala, Nelson Chao, Parameswaran Hari, Javier Bolaños-Meade, Ronald Gress, Niels Smedegaard Anderson, Yi-Bin Chen, Umar Farooq, Gary Schiller, Jean Yared, Anna Sureda, Timothy S Fenske, Horatiu Olteanu
Aggressive NK cell leukemia (ANKL) is an exceedingly rare form of leukemia and carries a poor prognosis, with a median survival of only 2 months. Using the Center for International Blood and Marrow Transplant Research database, we evaluated outcomes of allogeneic hematopoietic cell transplantation (alloHCT) in patients with ANKL. Twenty-one patients with a centrally confirmed diagnosis of ANKL were included. Median patient age was 42 years and 15 patients (71%) were Caucasian. Fourteen patients (67%) were in complete remission (CR) at the time of alloHCT, and 5 patients had active disease...
February 1, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28119528/outcomes-of-ucb-transplantation-are-comparable-in-flt3-aml-results-of-cibmtr-eurocord-and-ebmt-collaborative-analysis
#3
C Ustun, F Giannotti, M-J Zhang, H-L Wang, C Brunstein, M Labopin, V Rocha, M de Lima, F Baron, B M Sandmaier, M Eapen, E Gluckman, A Nagler, D J Weisdorf, A Ruggeri
Allogeneic hematopoietic cell transplantation (HCT) from siblings or unrelated donors (URD) during complete remission (CR) may improve leukemia-free survival (LFS) in FLT3+ acute myeloid leukemia (AML) that has poor prognosis due to high relapse rates. Umbilical cord blood (UCB) HCT outcomes are largely unknown in this population. We found that compared with sibling HCT, relapse risks were similar after UCB (n=126), (HR 0.86, P=0.54) and URD (n=91) (HR 0.81, P=0.43). UCB HCT was associated with statistically higher non-relapse mortality compared with sibling HCT (HR 2...
January 25, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28115276/allogeneic-hematopoietic-cell-transplantation-for-adult-chronic-myelomonocytic-leukemia
#4
Hien Duong Liu, Kwang Woo Ahn, Zhen-Huan Hu, Mehdi Hamadani, Taiga Nishihori, Baldeep Wirk, Amer Beitinjaneh, David Rizzieri, Michael R Grunwald, Mitchell Sabloff, Richard F Olsson, Ashish Bajel, Christopher Bredeson, Andrew Daly, Yoshihiro Inamoto, Navneet Majhail, Ayman Saad, Vikas Gupta, Aaron Gerds, Adriana Malone, Martin Tallman, Ran Reshef, David I Marks, Edward Copelan, Usama Gergis, Mary Lynn Savoie, Celalettin Ustun, Mark R Litzow, Jean-Yves Cahn, Tamila Kindwall-Keller, Gorgun Akpek, Bipin N Savani, Mahmoud Aljurf, Jacob M Rowe, Peter H Wiernik, Jack W Hsu, Jorge Cortes, Matt Kalaycio, Richard Maziarz, Ronald Sobecks, Uday Popat, Edwin Alyea, Wael Saber
Allogeneic hematopoietic cell transplantation (HCT) is potentially curative for patients with chronic myelomonocytic leukemia (CMML); however, few data exist regarding prognostic factors and transplantation outcomes. We performed this retrospective study to identify prognostic factors for post-transplantation outcomes. The CMML-specific prognostic scoring system (CPSS) has been validated in subjects receiving nontransplantation therapy and was included in our study. From 2001 to 2012, 209 adult subjects who received HCT for CMML were reported to the Center for International Blood and Marrow Transplant Research...
January 20, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27991895/pre-existing-invasive-fungal-infection-is-not-a-contraindication-for-allogeneic-hsct-for-patients-with-hematologic-malignancies-a-cibmtr-study
#5
R T Maziarz, R Brazauskas, M Chen, A A McLeod, R Martino, J R Wingard, M Aljurf, M Battiwalla, C C Dvorak, B Geroge, E C Guinan, G A Hale, H M Lazarus, J-W Lee, J L Liesveld, M Ramanathan, V Reddy, B N Savani, F O Smith, L Strasfeld, R A Taplitz, C Ustun, M J Boeckh, J Gea-Banacloche, C A Lindemans, J J Auletta, M L Riches
Patients with prior invasive fungal infection (IFI) increasingly proceed to allogeneic hematopoietic cell transplantation (HSCT). However, little is known about the impact of prior IFI on survival. Patients with pre-transplant IFI (cases; n=825) were compared with controls (n=10247). A subset analysis assessed outcomes in leukemia patients pre- and post 2001. Cases were older with lower performance status (KPS), more advanced disease, higher likelihood of AML and having received cord blood, reduced intensity conditioning, mold-active fungal prophylaxis and more recently transplanted...
February 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27941764/gvhd-after-umbilical-cord-blood-transplantation-for-acute-leukemia-an-analysis-of-risk-factors-and-effect-on-outcomes
#6
Y-B Chen, T Wang, M T Hemmer, C Brady, D R Couriel, A Alousi, J Pidala, A Urbano-Ispizua, S W Choi, T Nishihori, T Teshima, Y Inamoto, B Wirk, D I Marks, H Abdel-Azim, L Lehmann, L Yu, M Bitan, M S Cairo, M Qayed, R Salit, R P Gale, R Martino, S Jaglowski, A Bajel, B Savani, H Frangoul, I D Lewis, J Storek, M Askar, M A Kharfan-Dabaja, M Aljurf, O Ringden, R Reshef, R F Olsson, S Hashmi, S Seo, T R Spitzer, M L MacMillan, A Lazaryan, S R Spellman, M Arora, C S Cutler
Using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, we analyzed 1404 umbilical cord blood transplantation (UCBT) patients (single (<18 years)=810, double (⩾18 years)=594) with acute leukemia to define the incidence of acute GvHD (aGvHD) and chronic GvHD (cGvHD), analyze clinical risk factors and investigate outcomes. After single UCBT, 100-day incidence of grade II-IV aGvHD was 39% (95% confidence interval (CI), 36-43%), grade III-IV aGvHD was 18% (95% CI, 15-20%) and 1-year cGvHD was 27% (95% CI, 24-30%)...
March 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27712033/reduced-intensity-conditioned-allograft-yields-favorable-survival-for-older-adults-with-b-cell-acute-lymphoblastic-leukemia
#7
Ashley E Rosko, Hai-Lin Wang, Marcos de Lima, Brenda Sandmaier, H Jean Khoury, Andrew Artz, Johnathan Brammer, Christopher Bredeson, Sherif Farag, Mohamed Kharfan-Dabaja, Hillard M Lazarus, David I Marks, Rodrigo Martino Bufarull, Joseph McGuirk, Mohamed Mohty, Taiga Nishihori, Ian Nivison-Smith, Armin Rashidi, Olle Ringden, Matthew Seftel, Daniel Weisdorf, Veronika Bachanova, Wael Saber
Older adults with B-cell acute lymphoblastic leukemia (B-ALL) have poor survival. We examined the effectiveness of reduced intensity conditioning (RIC) hematopoietic cell transplant (HCT) in adults with B-ALL age 55 years and older and explored prognostic factors associated with long-term outcomes. Using CIBMTR registry data, we evaluated 273 patients (median age 61, range 55-72) with B-ALL with disease status in CR1 (71%), >CR2 (17%) and Primary Induction Failure (PIF)/Relapse (11%), who underwent RIC HCT between 2001 and 2012 using mostly unrelated donor (59%) or HLA-matched sibling (32%)...
January 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/27641680/effect-of-recipient-age-and-stem-cell-source-on-the-association-between-donor-telomere-length-and-survival-after-allogeneic-unrelated-hematopoietic-cell-transplantation-for-severe-aplastic-anemia
#8
Shahinaz M Gadalla, Tao Wang, Casey Dagnall, Michael Haagenson, Stephen R Spellman, Belynda Hicks, Kristine Jones, Hormuzd A Katki, Stephanie J Lee, Sharon A Savage
We previously showed an association between donor leukocyte relative telomere length (RTL) and post-hematopoietic cell transplantation (HCT) survival in patients with severe aplastic anemia (SAA) who received bone marrow grafts at ages <40 years. Here, we tested the generalizability of the prior findings in an independent validation cohort and by recipient age and stem cell source in the combined discovery and validation cohorts. We used monoplex quantitative real-time PCR to measure RTL in: (1) a new SAA validation cohort of 428 patients (age range, ...
December 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27548466/metabolic-syndrome-and-cardiovascular-disease-following-hematopoietic-cell-transplantation-screening-and-preventive-practice-recommendations-from-cibmtr-and-ebmt
#9
REVIEW
Z DeFilipp, R F Duarte, J A Snowden, N S Majhail, D M Greenfield, J L Miranda, M Arat, K S Baker, L J Burns, C N Duncan, M Gilleece, G A Hale, M Hamadani, B K Hamilton, W J Hogan, J W Hsu, Y Inamoto, R T Kamble, M T Lupo-Stanghellini, A K Malone, P McCarthy, M Mohty, M Norkin, P Paplham, M Ramanathan, J M Richart, N Salooja, H C Schouten, H Schoemans, A Seber, A Steinberg, B M Wirk, W A Wood, M Battiwalla, M E D Flowers, B N Savani, B E Shaw
Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus and all cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with the estimated prevalence of MetS being 31-49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality...
February 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27496215/post-transplant-outcomes-in-high-risk-compared-with-non-high-risk-multiple-myeloma-a-cibmtr-analysis
#10
Emma C Scott, Parameswaran Hari, Manish Sharma, Jennifer Le-Rademacher, Jiaxing Huang, Dan Vogl, Muneer Abidi, Amer Beitinjaneh, Henry Fung, Siddhartha Ganguly, Gerhard Hildebrandt, Leona Holmberg, Matt Kalaycio, Shaji Kumar, Robert Kyle, Hillard Lazarus, Cindy Lee, Richard T Maziarz, Kenneth Meehan, Joseph Mikhael, Taiga Nishihori, Muthalagu Ramanathan, Saad Usmani, Jason Tay, David Vesole, Baldeep Wirk, Jean Yared, Bipin N Savani, Cristina Gasparetto, Amrita Krishnan, Tomer Mark, Yago Nieto, Anita D'Souza
Conventional cytogenetics and interphase fluorescence in situ hybridization (FISH) identify high-risk multiple myeloma (HRM) populations characterized by poor outcomes. We analyzed these differences among HRM versus non-HRM populations after upfront autologous hematopoietic cell transplantation (autoHCT). Between 2008 and 2012, 715 patients with multiple myeloma identified by FISH and/or cytogenetic data with upfront autoHCT were identified in the Center for International Blood and Marrow Transplant Research database...
October 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27315441/does-flt3-mutation-impact-survival-after-hematopoietic-stem-cell-transplantation-for-acute-myeloid-leukemia-a-center-for-international-blood-and-marrow-transplant-research-cibmtr-analysis
#11
Abhinav Deol, Salyka Sengsayadeth, Kwang Woo Ahn, Hai-Lin Wang, Mahmoud Aljurf, Joseph Harry Antin, Minoo Battiwalla, Martin Bornhauser, Jean-Yves Cahn, Bruce Camitta, Yi-Bin Chen, Corey S Cutler, Robert Peter Gale, Siddhartha Ganguly, Mehdi Hamadani, Yoshihiro Inamoto, Madan Jagasia, Rammurti Kamble, John Koreth, Hillard M Lazarus, Jane Liesveld, Mark R Litzow, David I Marks, Taiga Nishihori, Richard F Olsson, Ran Reshef, Jacob M Rowe, Ayman A Saad, Mitchell Sabloff, Harry C Schouten, Thomas C Shea, Robert J Soiffer, Geoffrey L Uy, Edmond K Waller, Peter H Wiernik, Baldeep Wirk, Ann E Woolfrey, Donald Bunjes, Steven Devine, Marcos de Lima, Brenda M Sandmaier, Dan Weisdorf, Hanna Jean Khoury, Wael Saber
BACKGROUND: Patients with FMS like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML) have a poor prognosis and are referred for early allogeneic hematopoietic stem cell transplantation (HCT). METHODS: Data from the Center for International Blood and Marrow Transplant Research (CIBMTR) were used to evaluate 511 adult patients with de novo AML who underwent HCT during 2008 through 2011 to determine whether FLT3 mutations had an impact on HCT outcomes. RESULTS: In total, 158 patients (31%) had FLT3 mutations...
October 2016: Cancer
https://www.readbyqxmd.com/read/27220265/changing-trends-of-unrelated-umbilical-cord-blood-transplantation-for-hematologic-diseases-in-patients-older-than-fifty-years-a-eurocord-center-for-international-blood-and-marrow-transplant-research-survey
#12
Hanadi Rafii, Annalisa Ruggeri, Fernanda Volt, Claudio G Brunstein, Jeanette Carreras, Mary Eapen, Eliane Gluckman, Daniel J Weisdorf
No abstract text is available yet for this article.
September 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27184625/metabolic-syndrome-and-cardiovascular-disease-after-hematopoietic-cell-transplantation-screening-and-preventive-practice-recommendations-from-the-cibmtr-and-ebmt
#13
Zachariah DeFilipp, Rafael F Duarte, John A Snowden, Navneet S Majhail, Diana M Greenfield, José López Miranda, Mutlu Arat, K Scott Baker, Linda J Burns, Christine N Duncan, Maria Gilleece, Gregory A Hale, Mehdi Hamadani, Betty K Hamilton, William J Hogan, Jack W Hsu, Yoshihiro Inamoto, Rammurti T Kamble, Maria Teresa Lupo-Stanghellini, Adriana K Malone, Philip McCarthy, Mohamad Mohty, Maxim Norkin, Pamela Paplham, Muthalagu Ramanathan, John M Richart, Nina Salooja, Harry C Schouten, Helene Schoemans, Adriana Seber, Amir Steinberg, Baldeep M Wirk, William A Wood, Minoo Battiwalla, Mary E D Flowers, Bipin N Savani, Bronwen E Shaw
Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus, and all-cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with an estimated prevalence of MetS of 31% to 49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality...
August 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27159181/can-we-agree-on-patient-reported-outcome-measures-for-assessing-hematopoietic-cell-transplantation-patients-a-study-from-the-cibmtr-and-bmt-ctn
#14
REVIEW
B E Shaw, S J Lee, M M Horowitz, W A Wood, J D Rizzo, K E Flynn
Much research into the impact of hematopoietic cell transplantation (HCT) on recipients' symptoms, functioning and health-related quality of life uses diverse patient-reported outcome (PRO) measures. Robust conclusions regarding PROs in HCT patients are constrained by methodological issues, including the use of multiple different and noncomparable assessment measures. We reviewed 114 publications addressing PROs in HCT patients. Although three multi-item measures were most frequently used (FACT-BMT, n=28; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30, n=26; and SF-36, n=26), 25 additional measures were used in more than one study...
September 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27108694/defibrotide-for-treatment-of-severe-veno-occlusive-disease-in-pediatrics-and-adults-an-exploratory-analysis-using-data-from-the-center-for-international-blood-and-marrow-transplant-research
#15
Christopher Strouse, Paul Richardson, Grant Prentice, Sandra Korman, Robin Hume, Bijan Nejadnik, Mary M Horowitz, Wael Saber
Veno-occlusive disease (VOD) is an early and serious complication of hematopoietic cell transplantation (HCT) that is associated with inferior survival, particularly when it is complicated by multiorgan failure (severe VOD). We evaluated the efficacy of defibrotide in the treatment of severe VOD using observational data from the Center for International Blood and Marrow Transplant Research (CIBMTR). Eight thousand three hundred forty-one patients treated by HCT between 2008 and 2011 were identified from the CIBMTR clinical database; 3...
July 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27090960/the-impact-of-palifermin-use-on-hematopoietic-cell-transplant-outcomes-in-children
#16
Wael Saber, Mei-Jie Zhang, Patricia Steinert, Min Chen, Mary M Horowitz
Clinical trials evaluating palifermin have enrolled few pediatric patients, precluding safety analyses in large groups of children. We compared hematopoietic cell transplantation (HCT) outcomes among pediatric patients who did or did not receive palifermin as a preventive treatment for oral mucositis. Pediatric patients and controls, matched for HCT and donor type, disease, disease status, and age, were selected from the Center for International Blood and Marrow Transplant Research database and a 1:3 matched cohort analysis was performed...
August 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27088379/autologous-transplant-remains-the-preferred-therapy-for-relapsed-apl-in-cr2
#17
C Ganzel, V Mathews, K Alimoghaddam, A Ghavamzadeh, D Kuk, S Devlin, H Wang, M-J Zhang, D Weisdorf, D Douer, J M Rowe, E Polge, J Esteve, A Nagler, M Mohty, M S Tallman
Despite their favorable prognosis, 10-20% of acute promyelocytic leukemia (APL) patients relapse. Reinduction therapy is often followed by autologous hematopoietic cell transplantation (auto-HCT). Arsenic trioxide (ATO) has become part of standard reinduction and is often followed by auto-HCT. Data on patients in CR2 were collected from two large transplant registries (Center for International Blood and Marrow Transplant Research (CIBMTR) and European Group for Blood and Marrow Transplant (EBMT)) and two specialty referral centers...
September 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27040394/efficacy-of-pharmacokinetics-directed-busulfan-cyclophosphamide-and-etoposide-conditioning-and-autologous-stem-cell-transplantation-for-lymphoma-comparison-of-a-multicenter-phase-ii-study-and-cibmtr-outcomes
#18
Christopher R Flowers, Luciano J Costa, Marcelo C Pasquini, Jennifer Le-Rademacher, Michael Lill, Tsiporah B Shore, William Vaughan, Michael Craig, Cesar O Freytes, Thomas C Shea, Mitchell E Horwitz, Joseph W Fay, Shin Mineishi, Damiano Rondelli, James Mason, Ira Braunschweig, Weiyun Ai, Rosa F Yeh, Tulio E Rodriguez, Ian Flinn, Terrance Comeau, Andrew M Yeager, Michael A Pulsipher, Isabelle Bence-Bruckler, Pierre Laneuville, Philip Bierman, Andy I Chen, Kazunobu Kato, Yanlin Wang, Cong Xu, Angela J Smith, Edmund K Waller
Busulfan, cyclophosphamide, and etoposide (BuCyE) is a commonly used conditioning regimen for autologous stem cell transplantation (ASCT). This multicenter, phase II study examined the safety and efficacy of BuCyE with individually adjusted busulfan based on preconditioning pharmacokinetics. The study initially enrolled Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients ages 18 to 80 years but was amended due to high early treatment-related mortality (TRM) in patients > 65 years. BuCyE outcomes were compared with contemporaneous recipients of carmustine, etoposide, cytarabine, and melphalan (BEAM) from the Center for International Blood and Marrow Transplant Research...
July 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27034534/a-proportional-hazards-regression-model-for-the-sub-distribution-with-covariates-adjusted-censoring-weight-for-competing-risks-data
#19
Peng He, Frank Eriksson, Thomas H Scheike, Mei-Jie Zhang
With competing risks data, one often needs to assess the treatment and covariate effects on the cumulative incidence function. Fine and Gray proposed a proportional hazards regression model for the subdistribution of a competing risk with the assumption that the censoring distribution and the covariates are independent. Covariate-dependent censoring sometimes occurs in medical studies. In this paper, we study the proportional hazards regression model for the subdistribution of a competing risk with proper adjustments for covariate-dependent censoring...
March 2016: Scandinavian Journal of Statistics, Theory and Applications
https://www.readbyqxmd.com/read/26989808/allogeneic-transplantation-provides-durable-remission-in-a-subset-of-dlbcl-patients-relapsing-after-autologous-transplantation
#20
Timothy S Fenske, Kwang W Ahn, Tara M Graff, Alyssa DiGilio, Qaiser Bashir, Rammurti T Kamble, Ernesto Ayala, Ulrike Bacher, Jonathan E Brammer, Mitchell Cairo, Andy Chen, Yi-Bin Chen, Saurabh Chhabra, Anita D'Souza, Umar Farooq, Cesar Freytes, Siddhartha Ganguly, Mark Hertzberg, David Inwards, Samantha Jaglowski, Mohamed A Kharfan-Dabaja, Hillard M Lazarus, Sunita Nathan, Attaphol Pawarode, Miguel-Angel Perales, Nishitha Reddy, Sachiko Seo, Anna Sureda, Sonali M Smith, Mehdi Hamadani
For diffuse large B-cell lymphoma (DLBCL) patients progressing after autologous haematopoietic cell transplantation (autoHCT), allogeneic HCT (alloHCT) is often considered, although limited information is available to guide patient selection. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified 503 patients who underwent alloHCT after disease progression/relapse following a prior autoHCT. The 3-year probabilities of non-relapse mortality, progression/relapse, progression-free survival (PFS) and overall survival (OS) were 30, 38, 31 and 37% respectively...
July 2016: British Journal of Haematology
keyword
keyword
115199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"